NSE · EMCURE · Pharmaceuticals
Emcure Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1,468 Cr with net profit ₹234 Cr — a 15.92% net margin, versus 18.25% the period before.
Shareholding
As of 2026-06-30
- Promoter77.83%
- Public8.83%
- FII4.88%
- DII8.46%
1,24,991 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.56× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #15 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 38.42 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 20.62 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 70.26 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,235 Cr | 344.55 | 18.14 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Emcure Pharmaceuticals Limited(this company) | ₹36,105 Cr | 148.26 | 7.29 | 18.67% | 10.04% |
AI analysis
AI-generated · google/gemini-2.5-flashEmcure Pharmaceuticals Limited is listed on the Indian markets with a market capitalization of Rs 33824 Cr. The company reported revenue of Rs 7968.78 Cr for the fiscal year ending March 2025. Its price-to-earnings (P/E) ratio is 64.09, with an EPS of Rs 16.74. The company has a debt-to-equity ratio of 0.49. Promoter holding stands at 77.8673% as of March 31, 2026.
Positives
- +The Return on Capital Employed (ROCE) is 21.7565%.
- +The debt-to-equity ratio is 0.49, indicating a moderate level of debt.
- +Promoter holding is high at 77.8673% as of March 31, 2026.
Negatives
- −The Price-to-Earnings (P/E) ratio is 64.09, which is relatively high.
- −Promoter pledge percentage is 0.04% of total promoter holding as of March 31, 2026.
- −The promoter holding has slightly decreased from 78.0807% in December 2024 to 77.8673% in March 2026.
Financial Performance
For the fiscal year ending March 2025, Emcure Pharmaceuticals Limited reported a revenue of Rs 7968.78 Cr and a net profit of Rs 681.332 Cr. The company's EPS was Rs 16.74. Quarterly revenues for the year ending March 2026 show a rising trend, from Rs 1467.7 Cr in March 2026 to Rs 2469.7 Cr in March 2026, with net profit also increasing from Rs 233.7 Cr to Rs 243.4 Cr over the same period.
Profitability & Returns
Emcure Pharmaceuticals Limited achieved a Return on Equity (ROE) of 12.8% and a Return on Capital Employed (ROCE) of 21.7565%. The company's EPS for the fiscal year ending March 2025 was Rs 16.74. The P/E ratio is 64.09, and the book value per share is Rs 159.61.
Balance Sheet
The company has a debt-to-equity ratio of 0.49. The book value per share is Rs 159.61. As of March 31, 2026, promoter pledges accounted for 0.04% of promoter holdings.
Ownership & Pledges
Public shareholding stands at 12.6849%. A small portion of promoter shares, 0.04%, is pledged as of March 31, 2026.
Shareholding History
Promoter holding has shown a slight decrease from 78.0807% in July 2024 to 77.8673% in March 2026. FII holding has increased from 1.7561% in July 2024 to 3.3521% in March 2026. DII holding has also increased from 3.0015% to 6.0957% over the same period. Public shareholding decreased from 17.1617% in July 2024 to 12.6849% in March 2026.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Emcure Pharmaceuticals Limitedshare price & fundamentals